To test the possibility for MELK to be developed as breast cancer prognostic marker, we conducted IHC in 87 human breast tissue samples: IDC (n = 39), ductal carcinoma in situ (DCIS) (n = 10), metastases to lymph nodes (n = 5), and benign (n = 33). This evidence concerns the gene MELK and breast carcinoma.